Skip to content

A Multicenter Clinical Study of rTMS for Parkinson's Disease

A Multicenter Clinical Study of rTMS for Parkinson's Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06009471
Enrollment
200
Registered
2023-08-24
Start date
2023-07-01
Completion date
2025-08-31
Last updated
2023-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's disease, repetitive transcranial magnetic stimulation(rTMS), Unified Parkinson's Disease Rating Scale (UPDRS), Montreal Cognitive Assessment Scale (MoCA), activity of daily living(ADL), PD Sleep Scale (PDSS), King's Parkinson's Pain Assessment (KPPS)

Brief summary

Through rTMS, motor dysfunction and non-motor dysfunction of PD patients can be improved, working and living ability and quality of life of patients can be improved, and social burden and family burden can be reduced.

Detailed description

According to the inclusion criteria, a total of 200 patients with Parkinson's disease were planned to be enrolled in each center, and randomly divided into control group (conventional treatment) and observation group (conventional treatment +rTMS) for a treatment cycle of 4 weeks. They were followed up for 3 months before treatment, 2 weeks and 4 weeks, respectively, after treatment, to evaluate the efficacy and function. The unified Parkinson's Disease Rating Scale (UPDRS) was used. Cognitive function assessment Monteller Cognitive Assessment Scale (MoCA); Barthel Index for daily living activities; Depression assessment Hamilton Depression Scale (HAMD); Hamilton Anxiety Scale (HAMA); Sleep assessment PD Sleep Scale (PDSS); Pain assessment King Parkinson's Pain Assessment (KPPS) and adverse events were recorded.

Interventions

OTHERRoutine treatment in Neurology

Routine treatment in Neurology department, including drug treatment,etc.

DEVICERoutine treatment in Neurology and rTMS

Add rTMS to routine treatment. Low frequency rTMS is often used to treat cortical hyperexcitability and high frequency rTMS to treat hypoexcitability

Sponsors

Affiliated Hospital of Nantong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

A total of 200 patients with Parkinson's disease were enrolled in each center and randomly divided into control group (routine treatment) and observation group (routine treatment +rTMS).

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Hoehn-YAHR classification is between 1 and 2; * Have a primary school education or above and can read the scale used in this study; * MoCA score between 20 and 24, mild cognitive impairment ; * Aged between 30 and 80, regardless of gender; * Voluntarily participate and sign informed consent.

Exclusion criteria

* patients with cerebrovascular accident, craniocerebral injury and other diseases affecting muscle tension; * patients with serious mental disorders and cognitive disorders who cannot cooperate with assessment; * patients with severe liver, kidney, heart dysfunction and severe physical disorders; * Implanted devices such as pacemakers are installed inside the body; * drug-induced Parkinson's syndrome or Parkinson's superposition syndrome; * Have a history of epilepsy; * Women during pregnancy and breastfeeding.

Design outcomes

Primary

MeasureTime frameDescription
Montreal Cognitive Assessment Scale (MoCA)The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.Full score of 30 points,\>=26 points normal,. Mild cognitive impairment (MCI) on a scale of 18-26, moderate on a scale of 10-17, and severe on a scale of\<10.
PD Sleep Scale (PDSS)The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.Evaluate the patient's sleep status, with a total of 15 items on the scale. Each item is scored on a scale of 0-10 points, with a lower score indicating poorer sleep status.
Activities of daily living Assessment - BarthelThe assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.The total score of the index is 100 points, and the higher the score, the better the self-care ability and the less dependence. Those scoring above 60 can basically complete basic Activities of daily living, 59-41 need some help to complete, 40-21 need a lot of help. Those who score below 20 are in complete need of help and cannot take care of themselves.
Unified Parkinson's disease rating Scale (UPDRS)The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.16 items, each with a score of 0-4, and the score is directly proportional to the severity of PD motor symptoms.
King's Parkinson's Pain Assessment (KPPS)The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.Evaluate the pain degree and quality of life of patients with Parkinson's disease, including 14 items in 7 aspects, including skeletal muscle pain, Chronic pain, symptom fluctuation related pain, nocturnal pain, orofacial pain, distention pain, and nerve root pain. Each score is expressed as pain severity (0-3 levels) multiplied by frequency (0-4 levels), that is, 0-12 points. The total score is 168 points. The higher the score, the more severe the pain.

Secondary

MeasureTime frameDescription
Hamilton Anxiety Scale (HAMA)The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.Include 14 projects. All items of HAMA adopt a 5-level scoring method of 0\ 4 points, and the criteria of each level are: (0) is Asymptomatic; (1) Light; (2) Moderate; (3) Heavy; (4) Extremely heavy. The total score of HAMA can better reflect the severity of anxiety symptoms. The total score can be used to evaluate the severity of anxiety symptoms and evaluate the effectiveness of various drugs and psychological interventions in patients with anxiety and depression disorders. According to the data provided by the collaborative group of the Chinese scale, if the total score exceeds 29 points, it may be severe anxiety; Above 21 points, there must be obvious anxiety; If the score exceeds 14, there must be anxiety; If the score exceeds 7, there may be anxiety; If the score is less than 7, there are no symptoms of anxiety. Generally speaking, the total score of HAMA is higher than 14 points, indicating clinically significant anxiety symptoms for the evaluated subject.
Hamilton Depression Scale (HAMD)The assessments are conducted at the baseline, 2nd week, 4th week, and 3 months after the end of treatment.Evaluate depressive status, including 14 5-level scoring items (0-4 points) and 10 3-level scoring items (0-2 points). Score\<8, no depression; 8 to 35 points, may be mild or moderate depression 35 points, may be severe depression.

Countries

China

Contacts

Primary ContactAisong Guo
guoasg@ntu.edu.cn15851300188

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026